Effects of Nepeta menthoides Boiss and Buhse on cognitive disorders in Dementia

Explanation of "Nesyan" in Iranian traditional medicine and study of effects of extract of Nepeta menthoides Boiss and Buhse on cognitive disorders in dementia a double blind clinical trial with placebo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015051022195N1

Enrollment

Registered

2015-11-15

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental and behavioural disorders. Unspecified dementia

Interventions

Intervention 1: Extract of Nepeta menthoides Boiss and Buhse in the form of 500 mg capsules three times in a day in the intervention group. Intervention 2: Starch in the form of 500 mg caps three ti

Treatment - Drugs

Placebo

Extract of Nepeta menthoides Boiss and Buhse in the form of 500 mg capsules three times in a day in the intervention group

Starch in the form of 500 mg caps three times a day in the control group

Eligibility

Sex/Gender

All

Age

65 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 65 to 85 years; Dementia diagnosis based on the baseline MMSE score less than 20 in the questionnaire by the psychiatrist; Have at least five classes of literacy; Obtain informed consent from the patient or the patient's guardian; No psychiatric disorder other than Alzheimer's disease according to a specialist such as depression and other diseases; Lack of substance abuse or drugs (except nicotine and caffeine); AChE inhibitors allergy history; History of heart disease, seizure, asthma, peptic ulcer, urinary tract obstruction; Reporting the warmth of humor based on valid and reliable questionnaire doctor Mujahid. Exclusion criteria: Drug side effects; Tend to withdraw from the project at any stage of the investigation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cognitive state. Timepoint: In the beginning and the end of prescription and three months following the treatment. Method of measurement: Mini Mental State Exam(folstein).	—

Secondary

Measure	Time frame
Side effects. Timepoint: During and three months after the treatment. Method of measurement: Symptoms and signs by the physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzam Abdolahadi

School of Traditional Medicine, Shahid Beheshti University of Medical Sciences

dr.abdolahadi@gmail.com+98 21 8883 7477

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026